Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2023-04-14
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab
Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large
B-Cell Lymphoma or Mantle Cell Lymphoma.